ECONOMICAL IMPACT OF ORCHIECTOMY FOR ADVANCED PROSTATE CANCER

ADRIANO A. P. DE PAULA, HILTON R. S. PICCELLI, NILSON P. PINTO, ANTONIO G. TELES, ANTONIO G. FRANQUEIRO, ADRIANO R. L. MALTEZ, JOSE H. SILVA

Section of Oncological Urology, Araujo Jorge Hospital, Association Against Cancer of Goias (ACCG), Goiania, Góias, Brazil

ABSTRACT

Purpose: To demonstrate the economical impact of surgical castration in comparison to the medical castration for patients with advanced prostate cancer.

Material and Methods: Between January 2001 and December 2001, 32 patients with advanced prostate cancer underwent bilateral sub-capsular orchiectomy at our Hospital. The costs of this procedure were compared to the costs of medical castration with LH-RH analogues.

Results: The costs of the surgical procedure were extremely reduced when compared to published data on the medical treatment. Surgical castration did not have any stronger negative impact on the evolution of these patients when compared to medical castration.

Conclusion: Surgical castration is an efficient and low cost treatment for advanced prostate cancer.

Key words: prostate; prostatic neoplasms; castration; therapy; costs and cost analysis; androgen antagonists

INTRODUCTION

Most prostate cancers are hormone-dependent; this means that they need testosterone for disease progression. Ninety percent of testosterone is produced by Leydig cells of the testis, whereas adrenal glands account for 5% of this production. Survival after treatment can reach 10 to 15 years as shown by Johansson & Ljunggren (1981).

The simplest way to get a hormonal blockade is bilateral orchiectomy, a procedure described by Huggins & Hodges (1). Riba (1942) modified the original technique to avoid an empty scrotum and described the subcapsular bilateral orchiectomy. The advantages of this technique are shown in Table-1.

The most popular treatment to reach hormonal blockade is the use of LH-RH analogues. The greatest problem of this modality of treatment is its high cost, especially if there is an expectation of extended survival, as is currently observed in the literature. Other disadvantages are shown in Table 2 (2).

Hormonal blockade can also be achieved by using estrogens, steroidal anti-androgens and non-steroidal anti-androgens, but none of these methods is more effective or has fewer side effects than surgical castration (3,4). Not even maximal blockade has shown better results when compared to orchiectomy alone or to the single use of LH-RH analogues (only 3 out of 27 randomized trials showed the benefits of maximal blockade) (5,6).

Great savings can be achieved when LH-RH analogues are replaced by bilateral orchiectomy, even when the latter is adopted after hormone refractory disease.

MATERIALS AND METHODS

Thirty-two patients with advanced prostate cancer underwent bilateral orchiectomy at our Hos-
All patients had T3, T4 or any T adenocarci-
noma of the prostate with bone metastasis.
Bilateral orchiectomy was indicated to these
patients, in view of the need for continuous treatment.
It was adopted as primary procedure or as replace-
ment of another hormonal blockade. All patients were
informed on the details of the surgical procedure, its
risks and its possible complications.

The operation was performed under local
anesthesia and sedation, and there were no in-patients.
The mean time of the procedure was 17 minutes, and
100 mg i.v. of cetoprofen and 1g i.v. cefazolin were
routinely administrated.

Data on patients and their biochemical evo-
lution are shown in Table-3. The mean age of the pa-
tients was 73.81, ranging from 59 to 93. Eighteen
patients had a Gleason score of up to 6, and 5 pre-
sented figures above 7.

Table 2 – Disadvantages of LH-RH analogues for ad-
vanced prostate cancer.

• Continuous or periodic treatment (long-life)
• Negative psychological effects due to the continuous
treatment
• High costs to public and private health care companies
• Risk of non-effective medication if not well stored
• Need of anti-androgens to avoid “flare”
• High cost

The “Unified Health System”, which com-
prises public health-care in Brazil, covered the costs
of all patients.

RESULTS

None of the patients stayed in hospital for
more than 12 hours on the day of surgery.
The median follow up was of 11.43 months.
Eight patients had taken anti-androgens be-
fore the procedure. In this work only 4 patients re-
quired anti-androgens after surgery to control rising
PSA, whereas the PSA levels of 27 of them decreased
after the intervention. The lowest nadir obtained was
0.08 ng/mL.
Four patients showed no PSA decrease 30
days after orchiectomy, but 3 of them had already been
diagnosed for hormone refractory disease.
Two patients died of prostate cancer, respec-
tively 5 and 9 months after surgery (at their first pre-
sentation, the former patient had a PSA level of 890
ng/mL and the latter had already been restricted to
bed due to bone metastasis at lumbar spine).
No patient required any medication other than
cetoprofen and paracetamol to control surgical pain.
Three patients presented scrotal hematoma
and were treated with antibiotics and local care.
No psychological complaints were referred
to the surgery.

DISCUSSION

The amount paid by the Brazilian public
health care for each bilateral orchiectomy was US$ 43.
The cost of surgical castration varies depending
on the country where it is performed and considering
different kinds of social security systems.
In the present context, a single dose of LH-
RH analogue costs 1.6 times more when compared to
the surgical procedure. Considering the median fol-
dow up of 11.41 months and the fact that those 30
patients remained alive at the end of this work, we
can estimate a total cost of US$ 33,387.63 with LH-
RH analogues.
The subcapsular technique bypasses the need
for prosthesis thus contributing to a lower cost when
compared to total orchiectomy. Chapman reported no
difference on testosterone and LH values when com-
paring subcapsular to total orchiectomy (7). Hering
et al. also showed no statistical difference between
total and subcapsular orchiectomy, nevertheless, re-
lated 43% of psychological side effects in the sub-
capsular group (8).

Side effects like mastalgia, gastric symptoms
and higher risk of deep vein thrombosis were not seen
in our work, but they are reported when estrogens or
anti-androgens are used (3,4).

Public health entities can reap significant
savings when castration is taken as a treatment for
advanced prostate cancer. Depending on the country,
a single dose of LH-RH analogue can be more ex-
pensive than bilateral orchiectomy.

This paper clearly shows that surgical castra-
tion, at our institution, is an efficient, inexpensive,
simple and low psychological effect modality of treat-
ment for advanced prostate cancer. In addition, the
quality of life of patients submitted to orchiectomy
was good, as has already been shown by several pa-
pers (11). This work shows that, if well informed,
patients with advanced prostate cancer accept bilat-
eral orchiectomy well.

Better results in relation to nadir could have
been achieved with a longer follow up, but this is not
the aim of the present work (10).

There will always be indication for other
hormone blockade modalities (mainly LH-RH ana-
logues) in situations such as intermittent treatment,
radiotherapy adjuvant or concomitant treatment or
even in cases in which the patient does not accept
surgical castration (9).

Mariani & Glover suggested that the savings
brought about by the substitution of LH-RH analogues
for surgical castration should be channeled to research
of new prostate cancer treatment modalities (12).

CONCLUSIONS

This work shows that bilateral subcapsular
orchiectomy is a low cost, efficient modality of treat-
ment for advanced prostate cancer at our institution.
Its acceptance is quite good and its psychological ef-
fects are almost inexistent.

We suggest the urologist who deals with pros-
tate cancer to consider the economical impact when
offering the different ways to treat advanced prostate
cancer, or, at least, to propose surgical castration when
the diagnosis of hormone refractory disease is made.

REFERENCES

1. Huggins C, Hodges CV: Studies on prostatic cancer:
the effect of castration of estrogen and of androgen
injection on serum phosphatases in metastatic
2. Stricker HJ: Luteinizing hormone-releasing hormone
EDITORIAL COMMENT

The authors should be congratulated for the choice of their theme. They have the merit and the courage to discuss an infrequent issue in the literature due to obvious reactions it may induce. Although the study deals superficially with the aspect of the effectiveness of the treatment and does not allow us to draw conclusions about it, it is direct to the point about its central issue: orchiectomy is much cheaper than medical castration. In fact, the “Economical impact of orchiectomy for advanced prostate carcinoma: Comparison of serum testosterone and PSA levels. J Bras Urol. 1999; 25: 221-4 [in Portuguese].


Received: November 8, 2002
Accepted after revision: February 17, 2003

Correspondence address:
Dr. Adriano A. Peclat de Paula
Hospital Araújo Jorge - Urologia
Rua 239, 181
Goiânia, GO, 74605-070, Brazil
Fax: + 55 62 202-4040
E-mail: adrianopaula@hotmail.com
very well. Based upon his reflections and his data, the amounts we would spend on LH-RH analogues for just one patient of non hormone-refractory advanced disease (in an average of 30 months) would be the following: US$ 43 x 1.6 x 30 months. This means that each medical castration costs 4700% more than the US$ 43 that are spent on an orchiectomy. Moreover, the medical procedure does not offer any logical benefit and shows the same results in terms of the patient’s survival. These resources could benefit 48 patients with the definitive surgery, without taking into consideration those approximately 15% of the patients who possibly would end up migrating into the surgical treatment. In other words, for each patient treated with LH-RH analogue, we could perform an orchiectomy in one patient and still offer the access to 47 other patients to surgeries of the same type. In terms of public health, our leaders should consider these issues.

A survey held among medical doctors in the USA has indicated that 68-81% of the American urologists recommend medical anti-androgenic therapy (2). Another study has further demonstrated that when the patient is invited to choose his own treatment freely after being informed of his possibilities, 70% also prefer the medical treatment. However, when 20% of the costs of the treatment are asked for as a counterpart on the part of the patient, only 24% choose medication (1). These figures, in addition to the fact that both treatments offer the same results, cast some doubt over the premise. They suggest the need for us to undertake studies about these types of treatment and their consequences on the patient’s self-esteem, on his physical appearance and especially on his quality of life considering our socio-cultural and economical situation. An inadequate and unreal resource policy is not fair and may limit the benefit to many other patients.

References

Dr. Homero Arruda
Division of Urology
Federal University of São Paulo
São Paulo, SP, Brazil

EDITORIAL COMMENT

Orchiectomy was the first efficient treatment for advanced prostate cancer since the work of Huggins & Hodges, cited in the article. It is still used, which proves its value.

Many drugs have been developed to treat this disease. Each of them acts differently, but all have the same aim. However, these drugs are difficult to dose and especially their price render them inaccessible to a great part of our population, which leads our patients to abandon treatment quickly and to suffer the consequences of the disease.

Among institutional patients, we notice that even with free distribution of the drug, the rate of adherence to the treatment is not as high as desired,
which usually occurs due to the socio-economical and cultural level of these patients. Another important factor to be considered are the side-effects of many of these drugs, as well as the absolute contraindication of some drugs for patients with deep vein thrombosis.

Sub-capsular orchiectomy is an excellent option for these patients, since it is a definitive treatment, has minimal side-effects and no contraindication, and it avoids psychological trauma due to an empty scrotum.

It has been questioned whether sub-capsular orchiectomy would be as efficient as total orchiectomy. However, recent studies show that beyond being equally effective, the former is more economical, since it bypasses the need for a testicular prosthesis and disagreeable psychological side-effects (1).

This article thus demonstrates that in terms of effectiveness and costs, sub-capsular orchiectomy is extremely efficient for the treatment of advanced prostate cancer, being more economical, avoiding difficulties with doses and side-effects and keeping the esthetics of the scrotum.

Reference

Dr. Flávio Hering
Division of Urology
Federal University of São Paulo
São Paulo, SP, Brazil